People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...